Valeant looking to grow further but Meda rules itself out
This article was originally published in Scrip
Executive Summary
"We have acquired several attractive assets in the past few years that have bolstered our presence [in dermatology] across our geographic markets and we will continue to look for other assets that will continue this growth," said Valeant Pharmaceuticals' CEO J. Michael Pearson as recently as two weeks ago.